LGD-2226

LGD-2226 is a selective and orally active androgen receptor modulator with an EC50 of 0.2 nM and a Ki of 1.5 nM for human androgen receptor. LGD-2226 shows tissue selectivity in animal models, with reduced effects on prostate compared to muscle. LGD-2226 can be used for muscle wasting, osteoporosis and sexual dysfunction[1][2].

Product Specifications

CAS Number

[328947-93-9]

UNSPSC

12352200

Hazard Statement

H302, H315, H319, H335

Target

Androgen Receptor

Type

Biochemical Assay Reagents

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lgd-2226.html

Purity

98.58

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C1NC2=C(C=C(N(CC(F)(F)F)CC(F)(F)F)C=C2)C(C(F)(F)F)=C1

Molecular Formula

C14H9F9N2O

Molecular Weight

392.22

Precautions

H302, H315, H319, H335

References & Citations

[1]van Oeveren A, et al. Discovery of 6-N, N-bis (2,2,2-trifluoroethyl) amino- 4-trifluoromethylquinolin-2 (1H) -one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49 (21) :6143-6.|[2]Miner JN, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148 (1) :363-73.